Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Cofilin is an additional actin severing protein present in s
2025-01-16

Cofilin is an additional norethindrone acetate and ethinyl estradiol severing protein present in sperm cells that undergo phosphorylation/inactivation on serine 3 by Lim kinases (LIMK) and by Tes kinases (TESK) [48]. LIMK can be activated by several pathways, including one through the Rho/ROCK/LIMK
-
Antihypertensive agent Several tertiary prevention studies a
2025-01-16

Several tertiary prevention studies are currently underway examining the use of dutasteride for prostate cancer treatment: (1) during expectant management of prostate cancer, (2) after radical prostatectomy in men at high risk for relapse, and (3) in men with metastatic disease. The Reduction by Dut
-
br Disclosure statement br Acknowledgements The work
2025-01-15

Disclosure statement Acknowledgements The work was supported by the National Science Foundation of China (Nos. 81273526, 81473268) and Natural Science Foundation of Colleges and Universities (Nos. KJ2017A197). What is already known What this article adds Introduction Sevoflurane is o
-
There is little question that as we
2025-01-15

There is little question that as we become more proficient in the diagnosis of arginase 1 deficiency individuals with intermediary elevations in arginine on newborn screening and partial defects in enzymatic activity will be found. There are no reliable data to determine a safe level of arginine and
-
Mechanistically it was soon realized that in undead cells
2025-01-15

Mechanistically, it was soon realized that in undead cells, Dronc promotes the activation of Jun-N-terminal kinase (JNK) signaling as the major inducer of AiP [25], [28] (Fig. 2B,C). However, it has been unknown for a long time how active Dronc promotes JNK signaling. Recently, it was reported that
-
There is a delicate balance between ROS
2025-01-15

There is a delicate balance between ROS generation and scavenging by the protective antioxidant defenses in the cell. Antioxidant systems present in the BS-181 include enzymes like superoxide dismutase (SOD), catalases, glutathione peroxidases (GPxs) and peroxiredoxins (PRxs) (Fig. 3) [38]. SODs ar
-
br Economics consequences of antibiotic
2025-01-15

Economics consequences of antibiotic resistance in a SICU In the era of cost-containment, surgeons also need to consider the economic impact of antibiotic resistance in the surgical patient. Antibiotic-resistant infections are more difficult to treat, are more costly and more likely to be fatal t
-
Growth inhibition assays are the
2025-01-15

Growth-inhibition assays are the most commonly used to identify antifungal small molecules. However, they have several facts that limit their use since many pathogenic fungi grow as filaments making difficult a correlation between growth and OD (optical density). They are not useful for identifying
-
We provide here direct evidences that AT receptors are
2025-01-15

We provide here direct evidences that AT1 receptors are active in ADSCs since Ang II induces intracellular Ca mobilization in these cells. Data obtained during the observation of Ca influxes led us to the search for the ADSCs subpopulation constantly expressing AT1 receptor. ADSCs are necessary for
-
5,7-dihydroxychromone Immunohistochemistry Hearts from young
2025-01-15

Immunohistochemistry: Hearts from young and aged mice were collected at the indicated times, fixed overnight in 10% formalin, and embedded in paraffin. Serial 5-μm heart sections from each group were analyzed. Samples were stained with H&E for routine histologic examination. Immunohistochemical stai
-
br Results br Discussion Here we uncovered a role for
2025-01-15

Results Discussion Here, we uncovered a role for Wnt-Fz7 signaling in LTP-dependent spine plasticity and synaptic localization of AMPARs. We demonstrated that LTP induction increased Wnt7a/b protein at Cy5 hydrophilic fluorophore and spines. Direct blockade of endogenous Wnts impaired LTP-med
-
Small kinase inhibitors have been developed
2025-01-14

Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha
-
Earlier studies showed that exposure of cells to IR
2025-01-14

Earlier studies showed that exposure of cells to IR caused ATM-dependent phosphorylation of 53BP1, as judged by electrophoretic mobility shift [24], [25], [26]. To date, the only known in vivo 53BP1 phosphorylation site(s) are Ser25 and possibly Ser29 [27]. In the course of our studies, we noticed t
-
In summary the CV and renal benefits
2025-01-13

In summary, the CV and renal benefits of sacubitril/valsartan in HF patients are attributed to the increased levels of peptides that are degraded by neprilysin and the simultaneous inhibition of the effects of AT1 receptor by valsartan (Fig. 1). Physical and chemical properties Sacubitril/Valsar
-
A phase I trial has
2025-01-13

A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with
15783 records 38/1053 page Previous Next First page 上5页 3637383940 下5页 Last page